Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.

Thyroid : official journal of the American Thyroid Association - 1 Oct 2013

Kim Kevin B, Cabanillas Maria E, Lazar Alexander J, Williams Michelle D, Sanders Deborah L, Ilagan Joseph L, Nolop Keith, Lee Richard J, Sherman Steven I

Abstract excerpt

BACKGROUND: Clinical benefit from cytotoxic chemotherapy for metastatic papillary thyroid carcinoma (PTC) is disappointing, and effective therapeutic approaches for these patients are urgently needed. Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in advanced PTC, and inhibition of BRAF(V600E) has shown promising clinical activity in melanoma, BRAF inhibitor therapy may be an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Proto-Oncogene Mas

Share to Sulfonamides

Share to Thyroid Cancer, Papillary

Share to Tumor Burden

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 23489023
DOI: 10.1089/thy.2013.0057
PMCID: PMC3967415

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.PMID 23489023Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.Semantic proximity Read ↗

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Semantic proximity Read ↗

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).Semantic proximity Read ↗

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.Semantic proximity Read ↗

Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.Semantic proximity Read ↗

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.